Commentary

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Full Paper (English): TAG Paper: Observations on Drug Pricing and Innovation in Japan ENG

Full Paper (Japanese): TAG Paper: Observations on Drug Pricing and Innovation in Japan JPN

Key Findings

As the Government of Japan (GOJ) seeks to re-invigorate Japan’s pharmaceutical industry as a sector for innovation and growth, it can make impactful changes to specific pricing policies that will support Japanese patients’ access to the most innovative medicines.

The Asia Group (TAG) has identified two specific pharmaceutical pricing measures that directly undermine the government’s goal of promoting startups and bringing innovative new pharmaceutical products to market. The negative impact of these policies is particularly severe for innovative drugs for rare diseases, for which there are often no alternative treatments:

  1. Strict cost disclosure requirements, especially the “co-factor zero” rule introduced in the cost-based price calculation method in 2022, are effectively canceling out many premiums that were intended to reward innovation and novelty.
  2. Corporate status criteria associated with the Price Maintenance Premium (PMP) system favor companies with a long track record of business in Japan and limit premium benefits for new market entrants.

The intended purpose of these rules is to improve transparency in a product’s total cost and provide incentives for drug launches in Japan. But the two-fold impact of these rules, particularly penalizing new market entrants and foreign entrants, has undermined the intended effect of these measures.

Eliminating these two specific punitive pricing policies represents “low-hanging fruit” for policy change, which can have an immediate impact on the availability of novel drugs, while having a relatively low impact on Japan’s healthcare budget. These changes will stimulate future successful launches and early entrance to Japan, benefitting patients.

Related Posts

TAG Managing Partner, Kurt Tong Speaks on Ishiba-Trump Meeting to The Japan Times
“My best guess would be that if the U.S. does some kind of blanket global policy on reciprocal tariffs, that ...
The Asia Group Welcomes Ambassador Daniel J. Kritenbrink as Partner
Washington, DC | February 10, 2025 – The Asia Group (TAG) is excited to announce that Ambassador Daniel J. Kritenbrink, ...
TAG Vice President Yuka Hayashi Comments on Ishiba-Trump Summit to Bloomberg
“By highlighting what Japan could do to help Trump’s America First agenda, Ishiba offered a template for other countries to ...
TAG Principal Jennifer Lee Spoke to NBC News on the Prospects of a Meeting Between U.S. President Donald Trump and South Korea’s Acting President Choi Sang-mok
“There is no way that Trump will actually engage directly” with an acting president, said Jennifer Lee, a principal at ...
Scroll to Top

You Are Applying For:

TAG Paper: Observations on Drug Pricing and Innovation in Japan

Apply Now

Submit the details below, and our HR team member will get in touch with you shortly.

The Asia Group is an equal opportunity employer where an applicant’s qualifications are considered without regard to race, color, religion, sex, national origin, age, disability, veteran status, genetic information, sexual orientation, gender identity or expression, or any other basis prohibited by law. The Asia Group continually seeks to diversify its staff, particularly to broaden opportunities for individuals from demographic groups that are historically underrepresented in the strategic advisory profession.

"*" indicates required fields

1Personal Details
2Questionnaire & Application Materials
3Voluntary Self Identification

Personal Details

Name*
Address*